HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Oncolytics Biotech (NASDAQ:ONCY) and maintained a price target of $5.
January 04, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms Buy rating and $5 price target for Oncolytics Biotech, potentially bolstering investor confidence.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst could lead to increased investor confidence and a positive short term impact on ONCY's stock price. Analyst ratings are influential in the market and can affect stock prices, especially when they come from established firms like HC Wainwright & Co.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100